Somite AI lands $47m to leverage AI for ‘human regeneration and repair’

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Startup targets developmental biology’s ‘AlphaFold moment’ with foundation model that improves how cells are produced for cell therapies.

Boston-based startup Somite AI emerged this week, securing over $47 million in a Series A funding round led by Khosla Ventures for its mission to accelerate the development of human cell therapies using AI. The company is building a proprietary AI platform and foundation model called “DeltaStem”, which is designed to change the way cell therapies are discovered, developed and deployed.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Danny Sullivan

Danny has worked in technology communications for more than 20 years, and has been writing about developments the longevity sector since 2019. With a keen interest in the transfer of technology to market, he focuses primarily on the companies working on cutting-edge solutions to aging and age-related diseases.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Evommune bets $30m upfront on a new autoimmune drug

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE